

POSTER PRESENTATION

Open Access

Developing an immunotherapy strategy for the effective treatment of patients with squamous cell carcinoma of the head and neck

Tarsem Moudgil^{1*}, R Bryan Bell², Rom Leidner², Rieneke Van de Ven¹, Zipei Feng^{1,3}, Michael Affentoulis¹, Christopher Paustian¹, Christopher Dubay¹, Traci L. Hilton⁴, Walter J. Urba¹, Hong-Ming Hu¹, Carlo B. Bifulco⁵, Bernard A. Fox^{1,3}

From Society for Immunotherapy of Cancer 28th Annual Meeting
National Harbor, MD, USA. 8-10 November 2013

Squamous cell carcinoma of the head and neck (HNSCC) arises in the oral cavity, oropharynx, larynx or hypopharynx, and is the 6th leading cause of cancer by incidence worldwide. Approximately 600,000 cases arise each year, and only 40-50% of these patients will survive for 5 years. HNSCC can express PD-L1 and suppressive factors that interfere with the differentiation and activation of dendritic cells and effector function of T cells. Similar to observations in other malignancies, CD8 effector T cell infiltration or transcriptional signature consistent with an ongoing T cell response is associated with prolonged survival. This suggests that HNSCC lacking a T cell infiltrate may benefit from immune interventions that induce and/or augment a tumor-specific immune response. To develop a strategy to address this problem we have created a HNSCC tumor bank that is cryopreserving enzymatically isolated viable cells from resected tumors (39 specimens). We are also attempting to develop primary cell lines (4 lines established) and are isolating tumor-infiltrating lymphocytes from these specimens. We are looking to compare immunohistochemical, flowcytometric and functional analyses of these specimens. Consistent with previous studies, results document that isolated TIL secrete IFN- γ when stimulated with their autologous tumor cells (n=2). Since a central aim of these studies is to develop a strategy to create therapeutic immunity in patients lacking T cell infiltrates, we plan to investigate which antigens are recognized and whether, antigens present in a novel

DRibble vaccine, that expresses antigens common to HNSCC, are recognized by these TIL. This may provide a strategy to monitor anti-tumor immunity in these patients and possibly provide an antigen source for combination immunotherapy of patients with HNSCC.

Authors' details

¹Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Portland, OR, USA. ²Oral, Head and Neck Cancer Program and Clinic, Providence Cancer Center, Portland, OR, USA. ³Molecular Microbiology and Immunology, OHSU, Portland, OR, USA. ⁴UbiVac, Portland, OR, USA. ⁵Department of Pathology, Providence Cancer Center, Portland, OR, USA.

Published: 7 November 2013

doi:10.1186/2051-1426-1-S1-P262

Cite this article as: Moudgil et al.: Developing an immunotherapy strategy for the effective treatment of patients with squamous cell carcinoma of the head and neck. *Journal for ImmunoTherapy of Cancer* 2013 **1**(Suppl 1):P262.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



¹Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Portland, OR, USA

Full list of author information is available at the end of the article